EGFR and neoplasm: Tumor cells harboring classic variants are highly sensitive to first-, second-, or third-generation EGFR tyrosine kinase inhibitors (TKIs)such as erlotinib, gefitinib, afatinib, Furmonertinib,and osimertinib,etc.